1 unchanged sentence
Market and shareholder information
−Removed: Our ordinary shares are traded on the Nasdaq Global Select Market under the symbol “ALKS.” There were 112 shareholders of record for our ordinary shares on February 5, 2021.
+Added: Our ordinary shares are traded on the Nasdaq Global Select Market under the symbol “ALKS.” There were 105 shareholders of record of our ordinary shares on February 7, 2022.
In addition, the last reported sale price of our ordinary shares as reported on the Nasdaq Global Select Market on February 7, 2022 was $23.55.
1 unchanged sentence
We anticipate that we will retain all earnings, if any, to support our operations and our proprietary drug development programs.
−Removed: Any future determination as to the payment of dividends will be at the sole discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements and other factors our board of directors deems relevant.
+Added: Any future determination as to the payment of dividends will be at the sole discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements and other factors that our board of directors deems relevant.
Repurchase of equity securities
2 unchanged sentences
We did not purchase any shares under this program during the year ended December 31, 2021.
−Removed: As of December 31, 2020, we had purchased a total of 8,866,342 shares at a cost of $114.0 million.
+Added: As of December 31, 2021, we had purchased a total of 8,866,342 shares under this program at a cost of $114.0 million.
The 2026 Term Loans include restrictive covenants that impose certain limitations on our ability to repurchase our ordinary shares.
−Removed: During the three months ended December 31, 2020, we acquired 5,367 Alkermes ordinary shares, at an average price of $17.54 per share related to the vesting of employee equity awards to satisfy withholding tax obligations.
+Added: During the three months ended December 31, 2021, we acquired 100,257 of our ordinary shares, at an average price of $29.30 per share related to the vesting of employee equity awards to satisfy withholding tax obligations.
Irish taxes applicable to U.S.
3 unchanged sentences
The statements do not constitute tax advice and are intended only as a general guide.
−Removed: Furthermore, this information applies only to ordinary shares held as capital assets and does not apply to all categories of shareholders, such as dealers in securities, trustees, insurance companies, collective investment schemes and shareholders who acquire, or who are deemed to acquire, their ordinary shares by virtue of an office or employment.
+Added: Furthermore, this information applies only to our ordinary shares held as capital assets and does not apply to all categories of shareholders, such as dealers in securities, trustees, insurance companies, collective investment schemes and shareholders who acquire, or who are deemed to acquire, their ordinary shares by virtue of an office or employment.
This summary is not exhaustive and shareholders should consult their own tax advisers as to the tax consequences in Ireland, or other relevant jurisdictions where we operate, including the acquisition, ownership and disposition of ordinary shares.
12 unchanged sentences
Irish tax on capital gains
−Removed: A shareholder who is neither resident nor ordinarily resident in Ireland and does not hold our ordinary shares in connection with a trade or business carried on by such shareholder in Ireland through a branch or agency should not be within the charge to Irish tax on capital gains on a disposal of our ordinary shares.
+Added: A shareholder who is neither resident nor ordinarily resident in Ireland and does not hold our ordinary shares in connection with a trade or business carried on by such shareholder in Ireland through a branch or agency, should not be within the scope of the charge to Irish tax on capital gains on a disposal of our ordinary shares.
Capital acquisitions tax
22 unchanged sentences
Nasdaq Biotechnology Index
−Removed: Selected Financial Data
−Removed: The selected historical financial data set forth below at December 31, 2020 and 2019 and for the years ended December 31, 2020, 2019 and 2018 are derived from our audited consolidated financial statements, which are included elsewhere in this Annual Report.
−Removed: The selected historical financial data set forth below at December 31, 2018 and for the years ended December 31, 2017 and 2016 are derived from audited consolidated financial statements, which are not included in this Annual Report.
−Removed: The following selected consolidated financial data should be read in conjunction with our consolidated financial statements, the related notes and “Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Annual Report.
−Removed: The historical results are not necessarily indicative of the results to be expected for any future period.
−Removed: Year Ended December 31,
−Removed: (In thousands, except per share data)
−Removed: Consolidated Statements of Operations Data:
−Removed: REVENUES ( 1) :
−Removed: Product sales, net
−Removed: Manufacturing and royalty revenues (2)
−Removed: Research and development revenue
−Removed: License revenue
−Removed: Total revenues
−Removed: Cost of goods manufactured and sold
−Removed: Research and development ( 3)
−Removed: Selling, general and administrative
−Removed: Amortization of acquired intangible assets
−Removed: Restructuring ( 4)
−Removed: Total expenses
−Removed: OPERATING LOSS
−Removed: OTHER INCOME (EXPENSE), NET
−Removed: LOSS BEFORE INCOME TAXES
−Removed: PROVISION (BENEFIT) FOR INCOME TAXES
−Removed: LOSS PER ORDINARY SHARE:
−Removed: BASIC AND DILUTED
−Removed: WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:
−Removed: BASIC AND DILUTED
−Removed: Consolidated Balance Sheet Data:
−Removed: Cash, cash equivalents and investments
−Removed: Long-term debt
−Removed: Shareholders’ equity
−Removed: On January 1, 2018, we adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“Topic 606”).
−Removed: Included in manufacturing and royalty revenues in 2018 is $26.7 million of royalty revenue representing our proportional share of the proceeds Zealand Pharma A/S (“Zealand”) sale to Royalty Pharma of certain royalty streams for products that utilize technology we had previously licensed to Zealand.
−Removed: In the fourth quarter of 2019, we acquired Rodin in a transaction accounted for as an asset acquisition and we expensed $86.6 million of in-process research and development (“IPR&D”) acquired as part of the transaction, as it was determined to have no alternative future use.
−Removed: In the fourth quarter of 2019, our board of directors approved a restructuring plan following a review of our operations, cost structure and growth opportunities (the “Restructuring”).
+Added: Not applicable.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.